April Bio Completes 340B Won Funding Round, Cedes Control to TKG Huchem

According to Herald Economics, April Bio completed a 340 billion won third-party equity placement to a consortium led by IMM Investment and TKG Huchem on July 24. TKG Huchem, investing approximately 150 billion won, will exercise operational control through board majority and holds call options on IMM's remaining stake.

Unlike traditional leverage buyouts focused on cost-cutting, this deal prioritizes sustained R&D and clinical funding while preserving April Bio's existing research independence. TKG Huchem will provide capital and operational expertise without replacing core research teams, similar to Orion's 2024 acquisition of Recochem Biosciences.